These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


72 related items for PubMed ID: 7400107

  • 1. Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction.
    Whitehouse D, Shah U, Palmer FB.
    J Clin Psychiatry; 1980 Aug; 41(8):282-5. PubMed ID: 7400107
    [Abstract] [Full Text] [Related]

  • 2. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE.
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [Abstract] [Full Text] [Related]

  • 3. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder.
    Pelham WE, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, Moorer S.
    Pediatrics; 1987 Oct; 80(4):491-501. PubMed ID: 3658567
    [Abstract] [Full Text] [Related]

  • 4. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder.
    Fitzpatrick PA, Klorman R, Brumaghim JT, Borgstedt AD.
    J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):226-34. PubMed ID: 1564023
    [Abstract] [Full Text] [Related]

  • 5. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [Abstract] [Full Text] [Related]

  • 6. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S.
    J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 10. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Feb; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 11. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network.
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
    Pan XX, Ma HW, Wan B, Dai XM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Aug; 10(4):471-4. PubMed ID: 18706164
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E.
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 19. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S.
    Clin Pharmacol Ther; 1999 Sep; 66(3):295-305. PubMed ID: 10511066
    [Abstract] [Full Text] [Related]

  • 20. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial.
    Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan 01; 32(1):145-9. PubMed ID: 17765380
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.